What Employers Need to Know About Cannabis, CBD, and Workplace Drug Testing
By Ben Hoffman, MD, MPH
Chief Medical Officer, WorkSTEPS
This article is part of an ongoing WorkSTEPS occupational health series exploring emerging risks, regulatory shifts, and prevention strategies impacting today’s workforce.
Key Insights
- A positive drug test does not automatically establish workplace impairment.
- Employers should treat positive results, impairment, off-duty use, policy violations, and federal requirements as separate issues.
- CBD, Delta-8, and hemp-derived Delta-9 products can create unexpected workplace drug testing risks.
- Effective workplace drug testing programs rely on clear policies, supervisor training, and consistent decision-making.
When employers discuss cannabis and workplace drug testing, the conversation often centers on positive test results. However, the more important question may be what those results actually mean.
As cannabis laws continue to evolve and cannabidiol (CBD), a cannabis-derived compound commonly found in wellness products, remains widely available, employers face increasing pressure to balance workplace safety, compliance obligations, and employee rights. According to the U.S. Food and Drug Administration (FDA), cannabis-derived products, including CBD, can vary in composition and labeling, creating potential confusion for consumers and employers alike.
At the same time, many organizations are discovering that some long-held assumptions about drug testing no longer reflect today’s realities.
A positive drug test usually establishes exposure within a specimen-specific window. It does not, by itself, prove that the employee was impaired at work.
That distinction has significant implications for workplace policy, safety programs, and employment decisions.
Understanding the Difference Between a Positive Test and Workplace Impairment
Many workplace drug testing challenges arise because several separate issues are treated as if they are the same thing.
Employers may be evaluating:
- A positive drug test result
- Observable workplace impairment
- Off-duty substance use
- A violation of company policy
- Qualification for a federally regulated position
While these factors may overlap, they do not automatically mean the same thing.
For example, an employee may test positive within a testing window but show no signs of workplace impairment. Likewise, an employee may appear unfit for duty due to fatigue, illness, medication side effects, or another medical condition unrelated to illegal drug use.
Treating every positive result as proof of impairment can create unnecessary legal, operational, and employee-relations challenges. Employers are often better served by understanding exactly what a test can and cannot tell them before making decisions.
As discussed in our previous Occupational Health series article on choosing the right workplace drug testing method, different testing methods answer different questions. Understanding those differences helps employers interpret results more effectively and make more informed decisions.
Why Cannabis Continues to Challenge Employers
Cannabis has complicated workplace drug testing in ways many traditional programs were never designed to address.
Tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, may affect coordination, judgment, attention, and reaction time. However, the relationship between a positive drug test and actual workplace impairment is not always straightforward. Unlike alcohol testing, there is currently no universally accepted workplace threshold that reliably establishes cannabis impairment across all situations. This creates a challenge for employers trying to balance safety with fairness and consistency.
Instead of relying solely on a laboratory result, organizations should consider the broader context, including:
- Workplace observations
- Job responsibilities
- Safety-sensitive duties
- Event timelines
- Company policies
- Applicable federal or state requirements
A positive result may be one piece of information. It is rarely the entire picture.
The CBD, Delta-8, and Delta-9 Challenge
Many employees assume products marketed as CBD are automatically safe from a workplace drug testing perspective. Unfortunately, that assumption can create problems.
Products labeled as CBD, full-spectrum hemp, Delta-8, or hemp-derived Delta-9 may contain varying amounts of THC. Manufacturing variability, contamination, inaccurate labeling, and product formulation can all affect what’s ultimately consumed. As a result, employees may unintentionally use products that increase their risk of producing a positive drug test result. This creates an important education opportunity for employers.
Organizations should not assume employees understand the distinction between CBD, hemp-derived products, Delta-8, Delta-9, and marijuana. Clear policy language and employee communication can help reduce confusion and support more informed decisions.
Supervisor Observations Still Matter
As workplace testing programs evolve, one principle remains unchanged: documented observations are critical. Supervisors should focus on objective, observable facts rather than attempting to diagnose substance use.
Examples may include:
- Changes in behavior
- Coordination difficulties
- Reduced alertness
- Impaired attention
- Unsafe actions
- Significant departures from normal performance
These observations help provide context that testing alone cannot provide.
When a legitimate safety concern exists, employers should follow established procedures, document findings carefully, and ensure decisions are based on multiple sources of information rather than a single data point.
Is Your Policy Keeping Up?
Many workplace drug testing policies were written before widespread cannabis legalization, CBD products, and emerging cannabinoids became common. Employers should periodically review whether their policies still reflect today’s workplace realities.
Questions worth asking include:
- Does the policy clearly distinguish impairment from a positive test result?
- Are safety-sensitive positions properly defined?
- Does the organization address CBD and hemp-derived products?
- Are supervisors trained to document reasonable suspicion appropriately?
- Are policies aligned with current federal and state requirements?
Organizations that proactively address these questions are often better positioned to make consistent and defensible decisions when challenging situations arise. Employers reviewing their testing programs may also benefit from broader Occupational Health Services support to help align workplace safety, compliance, and workforce health initiatives.
Conclusion
Cannabis, CBD, Delta-8, and hemp-derived Delta-9 products have introduced new complexity into workplace drug testing. As a result, employers can no longer assume that a positive drug test automatically answers every workplace safety question.
The most effective programs recognize the difference between substance exposure, workplace impairment, off-duty conduct, policy violations, and regulatory requirements. They combine testing with clear policies, supervisor observations, medical review, and thoughtful decision-making.
Ultimately, successful workplace drug testing programs are not built around a single test result. They are built around understanding what that result means, what it does not mean, and how it fits into the broader workplace safety picture.
Dr. Ben Hoffman, MD, MPH, is a highly seasoned physician executive with an extensive background in occupational and environmental health, clinical medicine, and transportation safety. He has worked with government agencies, nonprofits, and multinational corporations, including GE, Waste Management, Anheuser-Busch, and DuPont. Dr. Hoffman trained at Yale, Brown, and Mt. Sinai School of Medicine and is board certified in internal medicine, preventive medicine, and environmental/occupational health.
A widely published physician and academic, Dr. Hoffman holds an adjunct professorship at the University of Texas School of Public Health and has held professorships at Tufts University Friedman School of Nutrition, Dartmouth School of Medicine, Boston University, and the University of New Hampshire. His professional service includes numerous committees and boards, including Global Health at the National Academy of Sciences/Institute of Medicine, IPIECA, and the International Association of Oil & Gas Producers (OGP). He also previously served as chair of the U.S. DOT/FMCSA Medical Review Board.
